GLP-1 adoption just crossed a milestone. A Gallup survey released this week found that 11% of US adults now take a GLP-1 medication for weight loss — about 40 million people, roughly the population of California — up from just 3% two years ago. Over the same window, the national adult obesity rate posted its first significant decline on record, falling from a 2022 peak of 39.9% to 36.4% in 2026.
That is one of the fastest shifts in adoption of any prescription category in recent memory, and the two curves — usage rising, obesity falling — are moving in opposite directions for the first time since Gallup began tracking both.
Research-context information only. This article reports survey data and what it means for buyers. It is not medical advice. Talk to a licensed physician before starting any GLP-1 protocol. Retatrutide, mentioned below, is an investigational drug not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction.
For readers weighing a GLP-1, the headline number is less useful than the question underneath it: with demand this high and branded supply this expensive, how are 40 million people actually getting the drug — and what are the cheaper routes people are using?
What the Gallup Data Shows
The numbers come from Gallup's most recent health survey, conducted May 28-June 5, 2026 among 5,065 US adults across all 50 states; the obesity and diabetes figures pool two quarters of collection (Feb 28-March 3 and May 28-June 5) for a total of 10,091 respondents. Three findings stand out:
| Metric | 2024 | 2026 | Change |
|---|---|---|---|
| Adults currently using a GLP-1 for weight loss | 3% | 11% | nearly quadrupled |
| Adults who have ever used a GLP-1 for weight loss | 6% | 15% | +9 points |
| US adult obesity rate | — | 36.4% | down from 39.9% (2022 peak) |
The obesity decline is the part drawing attention. After 15 years of steadily rising obesity, a 3.5-point drop is the first meaningful reversal Gallup has recorded, and it tracks inversely with the GLP-1 curve. Gallup is careful to frame this as correlation, not proof — but the timing is hard to ignore.
Diabetes rates, notably, held steady. After a decade and a half of slow increases that mirrored the obesity climb, the diabetes-diagnosis rate has flattened since 2023 rather than continuing to rise.
The trend also has policy tailwind behind it. The Medicare GLP-1 Bridge went live July 1, 2026, opening a $50-copay path for roughly 3.8 million qualifying enrollees — a program that could push the next Gallup reading higher still.
What This Means for Buyers
The surge exposes the real bottleneck in the GLP-1 market: it is not demand, it is access. Branded weekly injectables still list north of $1,000/month, and even the manufacturer cash-pay programs run roughly $349-$499 — before the patchwork of insurance denials, prior authorizations, and step-therapy rules that gate most prescriptions. The Medicare Bridge helps a narrow slice of enrollees; it does nothing for the tens of millions who don't qualify.
That gap between record demand and gated, expensive supply is exactly why the research-grade market has grown alongside the prescription one. The same molecules driving the Gallup numbers — semaglutide, tirzepatide, and the investigational triple agonist retatrutide — are available as research-grade compounds from vetted vendors with current certificate-of-analysis documentation. These are sold for research purposes, not as a substitute for a physician-prescribed product. Industry and community reporting nonetheless describes self-pay buyers turning to this channel given the cost and access gaps outlined above.
Live pricing and COA status matter more than list price for buyers comparing options:
- Best Semaglutide Vendors — current pricing on 5mg and 10mg vials, with COA status
- Best Tirzepatide Vendors — the dual GLP-1/GIP agonist that trial data show outperforming semaglutide on weight, pricing on 10mg/30mg/60mg vials
- Best Retatrutide Vendors — the triple agonist with the highest weight-loss numbers in Phase 3 data to date
- All Active Vendor Coupons — current discount codes across recommended vendors
The honest framing: the Gallup data lines up with GLP-1s working at population scale — even if Gallup stops short of calling it causal — and demand is only accelerating. The open question for most buyers isn't whether to use one — it's which molecule, at what dose, and through which route they can actually afford and sustain.
